Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure Jun 3, 2019
Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference May 20, 2019
Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy Mar 21, 2019
Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai Mar 5, 2019
Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium Feb 28, 2019
